Evaluating 2'-Chlorodeoxyadenosine for Lymphoid Cancers
Author Information
Author(s): T. Hickish, P. Serafinowski, D. Cunningham, A. Oza, E. Dorland, I. Judson, B.C. Millar, T.A. Lister, A. Roldan
Primary Institution: Institute of Cancer Research, Royal Marsden Hospital
Hypothesis
Does 2'-Chlorodeoxyadenosine (2CDA) effectively treat lymphoid malignancies?
Conclusion
2CDA shows significant anti-tumor activity in pre-treated low grade non-Hodgkin's lymphoma and Hodgkin's disease.
Supporting Evidence
- 53% of patients responded to treatment with 2CDA.
- Three patients achieved complete remission and eight achieved partial remission.
- The median duration of response was 6 months.
Takeaway
This study tested a new drug called 2CDA on sick people with blood cancers, and it helped some of them feel better.
Methodology
Patients received 2CDA via intravenous infusion for 7 days, and their responses were evaluated using WHO guidelines.
Limitations
The study had a small sample size and included patients with varying degrees of previous treatment.
Participant Demographics
Patients included those with low grade non-Hodgkin's lymphoma, intermediate grade NHL, transformed NHL, Hodgkin's disease, lymphoplasmacytoid NHL, and lymphoblastic NHL.
Want to read the original?
Access the complete publication on the publisher's website